This decision is a blow for Eli Lilly and Novo Nordisk, who had both previously endorsed the proposed expansion.

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...